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Abstract
Introduction: In our earlier study, we found that pituitary adenomas, like other human tumours, express ectopically follicle stimulating 
hormone receptors (FSHR) in intratumoural blood vessels endothelia and/or tumoural cells. The aim of the present paper was to provide 
more detailed data on FSHR expression in different subtypes of pituitary adenomas and to evaluate its possible role as a prognostic and/
or predictive biomarker in these tumours.
Material and methods: Forty two pituitary adenomas, surgically removed, were immunostained with antibodies against the pituitary 
hormones, antigen Ki-67 and 1–190 fragment of FSHR.
Results: The positive FSHR immunostaining was found in blood vessels endothelia of 88% of adenomas and in tumoural cells of 40% 
adenomas. In tumoural cells, the incidence of at least moderate FSHR immunostaining is significantly higher in invasive tumours (68%) 
compared to non-invasive (12%) ones, and higher (albeit not statistically significantly) in invasive-proliferating adenomas (Ki-67 > 3%, 
grade 2b) compared to invasive but non-proliferating (Ki-67 < 3%, grade 2a) ones. 
Conclusions: The present study confirms that pituitary adenomas ectopically express FSHR in intratumoural blood vessels endothelia 
and tumoural cells. Moreover, the expression in tumoural cells is prevalent in invasive and proliferating adenomas vs. non-invasive and 
non-proliferating tumours. (Endokrynol Pol 2014; 65 (6): 469–471)
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Streszczenie
Wstęp: W poprzednich naszych badaniach stwierdziliśmy, że gruczolaki przysadki, podobnie jak inne ludzkie nowotwory, wykazują 
ektopową ekspresję receptorów folitropiny (FSHR) w śródbłonkach wewnątrzguzowych naczyń krwionośnych i/lub komórkach guza. 
Celem obecnej pracy jest bardziej szczegółowa ocena ekspresji FSHR w różnych subtypach gruczolaków przysadki i ocena jej roli jako 
biomarkera prognostycznego w tych guzach.
Materiał i metody: Czterdzieści dwa gruczolaki przysadki, usunięte chirurgicznie, zbadano immunohistochemicznie z użyciem przeciwciał 
przeciw hormonom przysadkowym, antygenowi Ki 67 i fragmentowi 1–190 ludzkiego FSHR.
Wyniki: Dodatni odczyn immunohistochemiczny na FSHR stwierdzono w wewnątrzguzowych naczyniach krwionośnych 88% badanych 
gruczolaków i w komórkach guzowych 40% badanych gruczolaków. W komórkach guzowych występowanie odczynu na FSHR o nasile-
niu co najmniej umiarkowanym było znamiennie wyższe w guzach inwazyjnych (68%) w porównaniu z guzami nieinwazyjnymi (12%) 
i wyższe (jakkolwiek nie znamienne statystycznie) w gruczolakach inwazyjnych proliferujących (Ki-67 > 3%, grade 2b) w porównaniu 
z guzami inwazyjnymi o niskiej proliferacji (Ki-67 < 3%, grade 2a). 
Wnioski: Obecna praca potwierdza, że gruczolaki przysadki wykazują ektopową ekspresję FSHR w wewnątrzguzowych naczyniach 
krwionośnych i komórkach guzów. Ekspresja w komórkach guzów przeważa w gruczolakach inwazyjnych i proliferujących w porów-
naniu z nieinwazyjnymi i o słabej proliferacji. (Endokrynol Pol 2014; 65 (6): 469–471)
Słowa kluczowe: receptor folitropiny (FSHR); gruczolaki przysadki; marker agresywności
Introduction 
Recent studies have revealed the ectopic expression 
of follicle stimulating hormone receptors (FSHR) in 
the endothelium of intra- and peritumoural blood 
vessels of several human neoplasms [1–4]. Moreover, 
in some tumours, like adrenal tumours [2], thyroid 
cancers [4], neuroendocrine tumours [3, 5], and soft 
tissue sarcomas [6], the expression of FSHR occurs 
also in tumoural cells. In our earlier study, we found 
also FSHR expression in the majority of pituitary 
adenomas [2]. 
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of FSHR in tumoural cells was found in 4/6 cases of 
acromegaly and in 13/27 cases of NFPA. Clinically non-
functioning adenomas are very heterogeneous consid-
ering their immunohistochemical phenotype (mainly 
they express gonadotropins). However, the incidence 
of FSHR is roughly similar in particular phenotype sub-
groups, perhaps with the exception of silent GH/PRL 
adenomas in which FSHR incidence is higher (5/6). The 
incidence of FSHR expression was significantly higher 
in invasive (68%) than in non-invasive tumours (12%; 
The aim of the present paper was to provide more 
detailed data on FSHR expression in different subtypes 
of pituitary adenomas and to evaluate its possible role as 
a prognostic and/or predictive biomarker in these tumours.
Material and methods
Tumour samples
Forty two pituitary adenomas, removed by transsphenoi-
dal adenectomy, were included in the study. On the basis 
of a clinical examination, six cases were diagnosed as acro-
megaly, seven as Cushing’s disease, two as prolactinoma, 
and 27 as clinically nonfunctioning adenomas (NFPA). The 
invasiveness of the tumours was estimated before surgery 
by means of magnetic resonance imaging. Ten tumours 
were classified as non-invasive and 25 as invasive. 
The study was approved by the Local Bioethical 
Committee, decision number RNN/537/11/KB.
Immunohistochemistry
The samples were fixed in 10% buffered formalin or 
Bouin-Hollande fixative. Paraffin sections (approx. 
5 μm thick) were immunostained using the rabbit anti-
human FSH-R polyclonal antibody sc-13935 purchased 
from Santa Cruz Biotechnology Inc. This antibody was 
raised against 1–190 amino acid sequence from the hu-
man FSH-R. In order to estimate the hormonal pheno-
type of the pituitary adenomas, immunohistochemical 
detection of pituitary hormones or their subunits was 
performed (for details see [2]) samples. Additionally, 
33 pituitary adenomas were also immunostained with 
anti-Ki-67 (MIB-1) antibody (Dako Cytomation) to es-
timate the proliferative status. The primary antibodies 
were applied in a working dilution of 1:100. The visu-
alisation of primary antibodies was done using either 
the StreptABComplex/HRP Duet (pituitary hormones 
and Ki-67) or the Dako REAL EnVision Detection Sys-
tem (FSHR). The immunoreaction intensity for FSHR 
protein in the tumoural cells was scored semiquanti-
tatively using a descriptive scale as follows: negative 
staining (score: 0), weak staining (score: 1), moderate 
staining (score: 2) and strong staining (score: 3). Only 
strong (score 3) or moderate (score 2) immunostaining 
was considered to be meaningful.
The statistical comparison of the data was per-
formed by means of c2 test corrected for small samples. 
As a positive control, a biopsy sample of the human 
testis was immunostained. As a negative control, the pri-
mary antibody was omitted in the staining procedure.
Results 
FSHR expression in tumoural cells was found in 17/42 
(40%) adenoma samples (Figs. 1 and 2). The expression 
Figure 1. The same tumour as in Figure 2 stained without the 
primary antibody. Original magnification 400×
Rycina 1. Ten sam guz jak na rycinie 2 barwienie bez pierwotnego 
przeciwciała. Oryginalne powiększenie 400×
Figure 2. Non-functioning pituitary adenoma (silent 
somatotropinoma) in a 71-year-old man. The positive FSHR 
immunostaining in tumoural cells and vascular endothelia 
(arrows) can be seen. Original magnification 400×
Rycina 2. Nieczynny hormonalne gruczolak przysadki 
(cichy somatotropinoma) u 71-letniego mężczyzny. Widoczny 
dodatni odczyn immunohistochemiczny FSHR w komórkach 
nowotworowych i komórkach śródbłonka naczyń (strzałki). 
Oryginalne powiększenie 400×
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p < 0.001). The incidence of FSHR immunostaining 
was also higher (albeit not statistically significantly) in 
invasive proliferating tumours (80%; Ki-67 > 3) grade 
2b according the classification of Trouillas et al. [7]) 
than in invasive but non proliferating (55%; Ki-67 < 
3%, grade 2a) ones. 
In contrast, no difference between primary (38%) 
and recurrent tumours (36%) was observed. The inci-
dence of at least moderate FSHR immunostaining is also 
about two-fold higher in primary tumours which later 
recurred within a 5-year period compared to those with-
out documented recurrence within this period (6/8; 75% 
vs. 5/14; 36%). As in other tumours, pituitary adenomas 
exhibit also ectopic FSHR expression in the endothelium 
of intratumoural blood vessels (Fig. 2). This expression 
was observed in 78% of tumours including all cases 
of acromegaly, all but one case of Cushing’s disease, 
and 70% of NFPA. There was no significant difference 
between recurrent and non-recurrent adenomas (73% 
vs. 81%, respectively). A tendency towards a higher 
incidence, albeit statistically not significant, could be 
observed in invasive vs. non-invasive tumours (71% 
vs. 60%) and in proliferating (Ki-67 > 3%) vs. non-
proliferating (Ki-67 < 3%) adenomas (85% vs. 64%).
Discussion
The present study confirms that pituitary adenomas 
ectopically express FSHR in intratumoural blood vessels 
endothelia and tumoural cells. Moreover, the expression 
in tumoural cells is prevalent in invasive and proliferat-
ing adenomas vs. non-invasive and non-proliferating 
adenomas. A similar tendency, although less evident, 
can be observed in respect of vascular endothelia. 
These findings corroborate with earlier observations 
concerning other human tumours. For instance, in li-
posarcomas, FSHR expression can be observed in more 
cases of dedifferentiated compared to well-diffentiated 
liposarcomas. The benign lipomas and non-neoplastic 
fat is FSHR negative [6]. In the thyroid, FSHR is strongly 
expressed in thyroid cancers (both differentiated and 
anaplastic), scarce in benign adenomas, and absent in 
normal thyroidal epithelium [4]. FSHR is also expressed 
in cultured androgen-independent prostate cancer 
cells, which are considered as less differentiated than 
androgen-dependent [8]. 
Thus, FSHR expression in pituitary adenomas, as 
in other tumours, may be considered as a marker of 
aggressiveness. However, its prognostic value as an 
exclusive marker seems to be limited. On the other 
hand, the overexpression of FSHR in pituitary adeno-
mas may constitute a novel therapeutic target in these 
tumours. It is known that in the normal ovary, as well 
as in ovarian cancer, FSH acting via its receptors leads 
to enhanced cell proliferation, decreased apoptosis and 
increased angiogenesis [9–11]. 
It may be hypothesised that ectopically expressed 
FSHR plays the same role in pituitary adenomas.
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